Christin’s note: Hi friends! It was super helpful to receive your feedback and support.

I want to let you know that I built a new iteration of Reframe Daily that might be more helpful—Reframe Scout is the new customizable email newsletter that lets you set your health topic(s) of choice and frequency (daily or weekly)! This was the original build I wanted to make and finally Claude Fable is able to make it happen.

I also made Gumleaf that texts you short and quick answers through SMS. Potentially useful for off-grid, places with bad cell data signals, dumb phone users, elderly friends? (It’s a US-based number so sorry, mostly for US audience and some Canadians if you have a plan that covers texts to the US!)

I’m traveling from today till next week so there won’t be new issues of Reframe Daily, and I’ll likely phase out this newsletter to focus on building more little apps. Many of you replied that you have been subscribed here to support me, for which I am super duper extremely grateful! So I have migrated you to my Substack where I’m centralizing all my updates 🙏 (if you are already there—wow, thank you!!)

Please always feel free to unsubscribe if you are tired of hearing from me / have too many emails these days, no hard feelings!!

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible health research updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: Scans plus simple blood markers spotted liver swelling and scarring in people with fatty liver disease, pointing to fewer biopsies; a lab method that reads many blood proteins at once in British South Asians linked inherited DNA changes to higher disease risk; mice that ate less of one protein building block stayed healthier longer, with some living longer; brain maps showed which areas change eating when a gut-hormone target is turned up or down to guide better appetite medicines

Good news: A study tested scans and simple blood markers that can spot liver swelling and scarring without a liver biopsy. If confirmed in more clinics, many people with fatty liver disease could avoid a painful procedure and still get the right care sooner.

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study

Market readiness: 🙂🙂🙂🙂 (The scans and blood tests already exist in many hospitals, and this study tests how well they work in a forward-looking way; to reach routine care, doctors still need agreed cutoffs, replication in more health systems, and guideline updates that say when biopsy can be skipped.)

Good news: Researchers used a new lab method to measure many blood proteins more clearly, which may help find hidden health risks earlier in some South Asian families. Over time, this kind of testing could support more personal prevention plans and point to new medicine targets.

Nanoparticle-enriched mass spectrometry proteomics in British South Asians identifies links between genetic variants, plasma protein levels and disease risk

Market readiness: 🙂🙂 (This is a promising lab-testing approach, but it is not yet a standard clinical test; it needs simpler, cheaper versions, clinical-grade validation, and proof that using the results changes care and improves outcomes.)

Good news: Mice that ate less of one amino acid stayed healthier longer, and some lived longer too. This hints that carefully changing specific parts of diet could one day help protect health during aging, but it has not been proven safe or helpful in people.

Lifelong restriction of dietary valine has sex-specific benefits for health and lifespan in mice

Market readiness: 🙂 (These results are in mice, not people; it would take careful human safety studies, long-term nutrition trials, and clear guidance to avoid malnutrition before anyone should try this as a health treatment.)

Good news: Scientists mapped which brain areas change eating when a gut-hormone drug target is turned up or down. This could help drug makers design appetite medicines that work better with fewer unwanted effects, but it is not yet a ready treatment by itself.

Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism

Market readiness: 🙂 (This is early-stage biology that guides future drug design; it needs follow-up work in people and clinical trials of specific new medicines before it can change patient care.)

Thank you for taking the time to take care of yourself and your loved ones.